View
Page
"FY16 results were strong, with 28% like-for-like total revenue growth reported (74% growth including the £2.7m contribution from its acquisitions late 2015). It has been a pivotal year for Abzena as it has expanded its business to provide a broad range of services from antibody discovery through to GMP manufacturing for Phase I/II trials. Alongside this, its clinical Abzena inside pipeline continues to grow, with 11 products now in the clinic and progressing toward commercialisation, most notably GS-5745 in gastric cancer." Note out from Edison yesterday on research tree
Welcome to the new Abzena stream forum! Messages posted in the Abzena stream will be logged here for posterity.
Latest from the Community...
Latest from the Community...
Latest from the Community...
